POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested to fight rare blood cancer
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to an existing treatment (ruxolitinib) could better control myelofibrosis, a serious bone marrow cancer. It involved 252 adults with intermediate or high-risk disease who had not previously taken similar medications. …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for blood cancer patients: trial tests combo therapy for tough cases
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to the standard treatment (ruxolitinib) could help people with myelofibrosis, a serious bone marrow cancer, who weren't getting a good enough response from ruxolitinib alone. It involved 177 participants and compared …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC